title: Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.
abstract: BACKGROUND Prostate cancer is a one of the most common malignant diseases in men worldwide. Now it is a challenge to identify patients at higher risk for relapse and progression after surgery, and more novel prognostic biomarkers are needed. The aim of this study was to investigate the clinical significance of protocadherin17 (PCDH17) methylation in serum and its predictive value for biochemical recurrence (BCR) after radical prostatectomy. MATERIAL AND METHODS We evaluated the methylation status of PCDH17 in serum samples of 167 early-stage prostate cancer patients and 44 patients with benign prostatic hyperplasia (BPH) using methylation-specific PCR (MSP), and then evaluated the relationship between PCDH17 methylation and clinicopathologic features. Kaplan-Meier survival analysis and Cox analysis were used to evaluate its predictive value for BCR. RESULTS The ratio of PCDH17 methylation in prostate cancer patients was higher than in patients with BPH. Moreover, PCDH17 methylation was significantly associated with advanced pathological stage, higher Gleason score, higher preoperative PSA levels, and BCR. Kaplan-Meier survival analysis indicated that patients with methylated PCDH17 had shorter BCR-free survival time compared to patients with unmethylated PCDH17. Cox regression analysis indicated that PCDH17 methylation was an independent predictive factor for the BCR of patients after radical prostatectomy. CONCLUSIONS PCDH17 methylation in serum is a frequent event in early-stage prostate cancer, and it is an independent predictor of BCR after radical prostatectomy.
authors.affiliation: Department of Urology, Xuzhou Cancer Hospital, Affiliated Xuzhou Hospital of Jiangsu University, Xuzhou, Jiangsu, China (mainland).
authors.forename: Ying-Li
authors.initials: YL
authors.lastname: Lin
authors.affiliation: Department of Orthopaedics, Qilu Hospital, Shandong University, Jinan, Shandong, China (mainland).
authors.forename: Qiu-Kui
authors.initials: QK
authors.lastname: Deng
authors.affiliation: Department of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
authors.forename: Yu-Hao
authors.initials: YH
authors.lastname: Wang
authors.affiliation: Health Science Center, Jiangsu University, Zhenjiang, Jiangsu, China (mainland).
authors.forename: Xing-Li
authors.initials: XL
authors.lastname: Fu
authors.affiliation: Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: Ma
authors.affiliation: Department of Urology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland).
authors.forename: Wen-Ping
authors.initials: WP
authors.lastname: Li
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D015820:Cadherins / Q000097:blood*; D006801:Humans; D008297:Male; D008745:Methylation; D009364:Neoplasm Recurrence, Local; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins; C529349:PCDH17 protein, human